Effect of Insulin Glulisine Compared to Insulin Aspart and Insulin Lispro When Administered by Continuous Subcutaneous Insulin Infusion (CSII) on Specific Pump Parameters in Patient With Type 1 Diabetes Mellitus.
Phase of Trial: Phase IV
Latest Information Update: 28 Jun 2012
At a glance
- Drugs Insulin aspart; Insulin glulisine; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms PUMP
- Sponsors Sanofi
- 31 Aug 2018 Biomarkers information updated
- 28 Jun 2012 Novo Nordisk and Eli Lilly added as associations as reported by European Clinical Trials Database.
- 24 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.